Prognosis of Hepatocellular Carcinoma: The BCLC Staging Classification
The DOI matches its Crossref record.
Abstract
The classifications of hepatocellular carcinoma (HCC) currently used are based on prognostic factors obtained from studies performed years ago when most tumors were diagnosed at advanced stages and the survival rates were substantially poor. Recent investigations have reviewed the survival of early tumors properly selected to receive radical therapies and the natural outcome of nonsurgical HCC patients. These data enable a new staging system to be proposed, the Barcelona Clinic Liver Cancer (BCLC) staging classification, that comprises four stages that select the best candidates for the best therapies currently available. Early stage (A) includes patients with asymptomatic early tumors suitable for radical therapies--resection, transplantation or percutaneous treatments. Intermediate stage (B) comprises patients with asymptomatic multinodular HCC. Advanced stage (C) includes patients with symptomatic tumors and/or an invasive tumoral pattern (vascular invasion/extrahepatic spread). Stage B and C patients may receive palliative treatments/new agents in the setting of phase II investigations or randomized controlled trials. End-stage disease (D) contain patients with extremely grim prognosis (Okuda stage III or PST 3-4) that should merely receive symptomatic treatment.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The management of patients with HCC has improved markedly since the first BCLC classification was proposed in 1999143.”
From Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024) · cites this paper as [143]
Citations
Cites
Still being checked.
Cited by
Items 1,001–1,005 of 1,005
Srivastava, S., Thakkar, B., Yeoh, K. G., Ho, K. Y., Teh, M., Soong, R., & Salto-Tellez, M. (2015) · Virchows Archiv · doi:10.1007/s00428-015-1745-4 · Cited by 22
Yoon, J. S., Lee, H. A., Park, J. Y., Kim, B. H., Lee, I. J., Chon, Y. E., Hong, S. K., Lee, D. H., Kong, H.-J., Won, Y.-J., et al. (2020) · Journal of Liver Cancer · doi:10.17998/jlc.20.1.41 · Cited by 19
Wang, L., Tian, F., Li, C., Wang, J., Dong, J., Cai, J., Yang, S., & Feng, X. (2025) · Patterns · doi:10.1016/j.patter.2025.101364 · Cited by 11
Targeting Dysregulated Ion Channels in Liver Tumors with Venom Peptides
Achimba, F., Faezov, B., Cohen, B., Dunbrack, R., & Holford, M. (2024) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-23-0256 · Cited by 6
Zhang, W., Chen, K., Tian, W., Zhang, Q., Sun, L., Wang, Y., Liu, M., & Zhang, Q. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.849242 · Cited by 2
Metadata
- Authors
- Llovet, J., Brú, C., & Bruix, J.
- Affiliations
- Consorci Institut D'Investigacions Biomediques August Pi I Sunyer (ES)
- Venue
- Seminars in Liver Disease
- Publisher
- Georg Thieme Verlag KG
- Published
- 1999
- Volume
- 19
- Issue
- 03
- Pages
- 329-338
- ISSN
- 0272-8087 (ISSN-L)
- 1098-8971
- OpenAlex
- W2147172608
- Cited by
- 3,805
- References
- 0
- Citations by year
- 2026: 70 · 2025: 117 · 2024: 162 · 2023: 211 · 2022: 269 · 2021: 280 · 2020: 279 · 2019: 215 · 2018: 206 · 2017: 218 · 2016: 216 · 2015: 220 · 2014: 219 · 2013: 163 · 2012: 154
- FWCI
- 11.18
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Seminars in Liver Disease (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
- Health Sciences › Medicine › Otorhinolaryngology › Head and Neck Cancer Studies
- Health Sciences › Medicine › Epidemiology › Hepatitis B Virus Studies
- Keywords
- hepatocellular carcinoma, prognosis, tumor staging, radical treatment, liver transplantation, hepatectomy, percutaneous treatment, vascular invasion, extrahepatic spread, palliative care, Okuda staging
- MeSH terms
- Carcinoma, Hepatocellular, Humans, Liver Neoplasms, Prognosis, Survival Rate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.